Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 24

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 24
---
 consolidated financial
statements of the Predecessor nor the Company as they are not directly attributable to either period but instead were contingent on the
Merger. The opening cash balance in the consolidated statement of cash flow of $1.88 million consists of $0.92 million from PBAX and $0.96
million from Predecessor. The number of shares of Common Stock issued and amounts recorded on the line within stockholders’ deficit
are reflected below to arrive at the opening consolidated balance sheet of the Company.

    Convertible  

    Preferred Stock  
    Series A  
    Additional  
    Stock  

    Series A  
    Common Stock  
    Paid-in  
    Subscription  
    Accumulated  

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Total 
  
    PBAX Closing Equity as of February 13, 2024 
     -  
    $-  
     54,812  
    $6  
    $541  
    $-  
    $(12,709,426) 
    $(12,708,879)
  
    Forfeiture of founders shares 
     -  
     -  
     (8,750) 
     (1) 
     1  
     -  
     -  
     - 
  
    Adjusted shares outstanding 
     -  
     -  
     46,062  
     5  
     542  
     -  
     (12,709,426) 
     (12,708,879)
  
    Shares issued as consideration in the Merger 
     -  
     -  
     80,750  
     8  
     47,238,742  
     -  
     -  
     47,238,750 
  
    Loss on VIE consolidation 
     -  
     -  
     -  
     -  
     -  
     -  
     (4,836,216) 
     (4,836,216)
  
    Expense IPR&D 
     -  
     -  
     -  
     -  
     -  
     -